Updated on 2024/03/29

写真a

 
FUJIKI Shinya
 
Organization
Graduate School of Medical and Dental Sciences Specially Appointed Assistant Professor
Title
Specially Appointed Assistant Professor
External link

Degree

  • Doctor(Medicine) ( 2011.3   Niigata University )

Research Interests

  • Cardiovascular medicine

Research Areas

  • Life Science / Cardiology

Research History (researchmap)

  • 新潟大学大学院医歯学総合研究科   循環器内科学

    2011.4

      More details

  • 新潟大学医歯学総合病院   初期臨床研修医

    2009.4 - 2011.3

      More details

Research History

  • Niigata University   Graduate School of Medical and Dental Sciences   Specially Appointed Assistant Professor

    2022.4

  • Niigata University   University Medical and Dental Hospital Cardiovascular Medicine   Assistant Professor

    2020.4 - 2022.3

Education

  • 新潟大学大学院医歯学総合研究科   循環器内科学

    2015.4 - 2020.9

      More details

  • Toyama Medical and Pharmaceutical University

    2003.4 - 2009.3

      More details

Professional Memberships

 

Papers

  • Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE Trial

    Daisaku Nakatani, Tomoharu Dohi, Shungo Hikoso, Atsushi Tanaka, Mamoru Nanasato, Wataru Shimizu, Koichi Node, Yasushi Sakata, Masayoshi Ajioka, Junya Ako, Rie Amano, Toshihisa Anzai, Mitsutoshi Asai, Kaoru Dohi, Kazuo Eguchi, Kenichi Eshima, Shinya Fujiki, Masashi Fujita, Shinya Hiramitsu, Satoshi Hoshide, Akihiko Hoshino, Yuki Ikeda, Yumi Ikehara, Takayuki Inomata, Teruo Inoue, Katsuhisa Ishii, Nobukazu Ishizaka, Masaaki Ito, Noriaki Iwahashi, Katsuomi Iwakura, Toshiaki Kadokami, Haruo Kamiya, Takahiro Kanbara, Yumiko Kanzaki, Ken Kashimura, Keisuke Kida, Kazuo Kimura, Satoru Kishi, Shuichi Kitada, Akihiro Kiyosue, Kazuhisa Kodama, Takayuki Kojima, Takumi Kondo, Yoshiaki Kubota, Kenya Kusunose, Noritaka Machii, Kazuo Matsunaga, Yasuto Matsuo, Yashushi Matsuzawa, Takeshi Mikami, Toru Minamino, Takahiro Nagai, Yasuko Nagano, Masashi Nagumo, Ikuko Nakamura, Katsunori Nakamura, Hiriyuki Naruse, Masami Nishino, Shinichi Niwano, Mitsutoshi Oguri, Nobuyuki Ohte, Masayoshi Oikawa, Takahiro Okumura, Masanori Okumura, Katsuya Onishi, Yukio Ozaki, Kan Saito, Tomohiro Sakamoto, Masashi Sakuma, Hisakuni Sekino, Kazuki Shiina, Michio Shimabukuro, Makoto Suzuki, Kunihiro Suzuki, Hiroyuki Takahama, Naohiko Takahashi, Yasuchika Takeishi, Shunsuke Tamaki, Akihiro Tanaka, Syuzo Tanimoto, Hiroki Teragawa, Tomoyuki Tobushi, Takafumi Toita, Kotaro Tokuda, Hirofumi Tomiyama, Hiroyuki Tsutsui, Hiroki Uehara, Masaaki Uematsu, Hirotaka Watada, Kazuyuki Yahagi, Takahisa Yamada, Hirotsugu Yamada, Tatsuya Yoshida, Akiomi Yoshihisa

    Journal of Cardiovascular Pharmacology   82 ( 1 )   61 - 68   2023.7

     More details

    Publishing type:Research paper (scientific journal)  

    Abstract:There were few clinical studies on the relationship between sodium glucose cotransporter 2 inhibitors (SGLT2i) and hematopoiesis in patients with diabetes (DM) and heart failure (HF) with consideration of systemic volume status. A total of 226 DM patients with HF enrolled in the CANDLE trial, a multicenter, prospective, randomized open-label blinded-endpoint trial, were studied. Estimated plasma volume status (ePVS) was calculated based on a weight-and hematocrit-based formula. At baseline, there was no significant difference in hematocrit and hemoglobin between the canagliflozin (n = 109) and glimepiride (n = 116) groups. Hematocrit and hemoglobin at 24 weeks, changes in hematocrit and hemoglobin difference (24 weeks-baseline), and hematocrit and hemoglobin ratio (24 weeks/baseline) were significantly higher in the canagliflozin than in the glimepiride group, respectively. There was no significant difference in ePVS at baseline and 24 weeks between the 2 groups. After adjustment for baseline parameters, canagliflozin correlated positively with changes in hematocrit and hemoglobin difference, and hematocrit and hemoglobin ratio by multivariate linear regression analyses. The difference in hematocrit and hemoglobin between the 2 groups became statistically significant at 3 and 6 months after randomization. There was no heterogeneity between canagliflozin and the characteristics of the patients for hematocrit and hemoglobin difference and ratio. A correlation of the changes in hematocrit and hemoglobin with cardiac and renal improvement was not observed. In conclusion, canagliflozin was associated with an increased hematocrit and hemoglobin in patients with diabetes and HF regardless of their volume status and characteristics.

    DOI: 10.1097/FJC.0000000000001430

    Scopus

    PubMed

    researchmap

  • Optimal Timing of Serial 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography after Prednisolone Treatment Introduction for Cardiac Sarcoidosis.

    Mitsuo Ishizuka, Takeshi Kashimura, Mitsuhiro Watanabe, Mayumi Kase, Ryohei Sakai, Takeshi Okubo, Shinya Fujiki, Tsugumi Takayama, Shiro Ishihara, Kazuyuki Ozaki, Takayuki Inomata

    International heart journal   64 ( 2 )   196 - 202   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Immunosuppressive therapy with prednisolone (PSL) is the first-line treatment for cardiac sarcoidosis (CS), and 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) is used to evaluate its efficacy to guide treatment. However, the appropriate timing of FDG-PET in CS remains unknown. This single-center, retrospective, observational study included 15 consecutive CS patients who underwent 3 serial FDG-PET scans (at baseline, in the early phase [1-2 months after PSL introduction], and in the late phase [≥ 5 months after PSL introduction with a maintenance dose of PSL]). We adhered to the PSL tapering protocol by the Japanese Circulation Society even when early FDG-PET showed positive results (SUVmax ≥ 4.0). No patient died during the 908 (644-1600) days of observation. Negative results in the late phase were observed in 3 of 6 early-positive patients, and 3 of 9 early-negative patients showed positive results in the late phase. Changes in echocardiographic parameters from baseline to the late phase were significantly better in late-negative patients than in late-positive patients (left ventricular end-diastolic diameter: -0.7 (-9.3-[-0.5]) mm versus +3.5 (0.8-7.5) mm, P = 0.039; left ventricular end-systolic diameter: -4.2 (-6.9-[-0.1]) mm versus +5.1 (0.5-7.0) mm, P = 0.015; left ventricular ejection fraction: +4.7% (-1.0-9.0%) versus -1.5% (-11.3-1.5%), P = 0.045) ), although early FDG-PET did not predict those consequent changes. An interval of ≥ 5 months after introducing the PSL with a maintenance dose of PSL is long enough for FDG-PET to reflect consequent left ventricular functions, while an interval of 1-2 months can be too short.

    DOI: 10.1536/ihj.22-406

    PubMed

    researchmap

  • Relationship Between Medical Therapy, Long-Term Care Insurance, and Comorbidity in Elderly Patients With Heart Failure With Systolic Dysfunction.

    Mayumi Kase, Shinya Fujiki, Takeshi Kashimura, Yuji Okura, Kunio Kodera, Hiroshi Watanabe, Kazuyoshi Takahashi, Shogo Bannai, Taturo Hatano, Takahiro Tanaka, Nobutaka Kitamura, Tohru Minamino, Takayuki Inomata

    Circulation journal : official journal of the Japanese Circulation Society   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Although guideline-directed medical therapy (GDMT), including β-blockers, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs), improves survival and quality of life, most patients with heart failure with reduced (HFrEF) and mildly reduced (HFmrEF) ejection fraction are treated with inadequate medications. We investigated the prescription patterns of GDMT in elderly patients with HFrEF and HFmrEF and their characteristics, including the certification of long-term care insurance (LTCI), which represents frailty and disability.Methods and Results: This retrospective cross-sectional study analyzed 1,296 elderly patients with symptomatic HFrEF and HFmrEF with diuretic use (median age 78 years; 63.8% male; median left ventricular ejection fraction 40%). Prescription rates of GDMT were inadequate (ACEi, ARBs, β-blockers, and MRAs: 27.0%, 30.1%, 54.1%, and 41.9%, respectively). LTCI certification was independently associated with reduced prescription of all medications (ACEi/ARB: odds ratio [OR] 0.591, 95% confidence interval [CI] 0.449-0.778, P=0.001; β-blockers: OR 0.698, 95% CI 0.529-0.920, P<0.001; MRAs: OR 0.743, 95% CI 0.560-0.985, P=0.052). Patients with LTCI certification also had a high prevalence of polypharmacy and prescription of diuretics. CONCLUSIONS: Vulnerable patients with LTCI may be an explanation for the challenges in implementing GDMT, and communicating is required for favorable heart failure care in this population.

    DOI: 10.1253/circj.CJ-22-0830

    PubMed

    researchmap

  • Effective Emergency Endovascular Treatment for Fatal Critical Limb Ischemia with Leriche Syndrome(タイトル和訳中)

    黒川 孝国, 齋藤 広大, 米山 晋太郎, 長谷川 祐紀, 藤木 伸也, 保屋野 真, 久保田 直樹, 大久保 健志, 池上 龍太郎, 柳川 貴央, 尾崎 和幸, 猪又 孝元

    日本循環器学会学術集会抄録集   87回   CROJ10 - 3   2023.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • Comprehensive genetic screening for vascular Ehlers-Danlos syndrome through an amplification-based next-generation sequencing system. International journal

    Tomomi Yamaguchi, Shujiro Hayashi, Daisuke Hayashi, Takeshi Matsuyama, Norimichi Koitabashi, Kenichi Ogiwara, Masaaki Noda, Chiai Nakada, Shinya Fujiki, Akira Furutachi, Yasuhiko Tanabe, Michiko Yamanaka, Aki Ishikawa, Miyako Mizukami, Asako Mizuguchi, Kazumitsu Sugiura, Makoto Sumi, Hirokuni Yamazawa, Atsushi Izawa, Yuko Wada, Tomomi Fujikawa, Yuri Takiguchi, Keiko Wakui, Kyoko Takano, Shin-Ya Nishio, Tomoki Kosho

    American journal of medical genetics. Part A   191 ( 1 )   37 - 51   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Vascular Ehlers-Danlos syndrome (vEDS) is a hereditary connective tissue disorder (HCTD) characterized by arterial dissection/aneurysm/rupture, sigmoid colon rupture, or uterine rupture. Diagnosis is confirmed by detecting heterozygous variants in COL3A1. This is the largest Asian case series and the first to apply an amplification-based next-generation sequencing through custom panels of causative genes for HCTDs, including a specific method of evaluating copy number variations. Among 429 patients with suspected HCTDs analyzed, 101 were suspected to have vEDS, and 33 of them (32.4%) were found to have COL3A1 variants. Two patients with a clinical diagnosis of Loeys-Dietz syndrome and/or familial thoracic aortic aneurysm and dissection were also found to have COL3A1 variants. Twenty cases (57.1%) had missense variants leading to glycine (Gly) substitutions in the triple helical domain, one (2.9%) had a missense variant leading to non-Gly substitution in this domain, eight (22.9%) had splice site alterations, three (8.6%) had nonsense variants, two (5.7%) had in-frame deletions, and one (2.9%) had a multi-exon deletion, including two deceased patients analyzed with formalin-fixed and paraffin-embedded samples. This is a clinically useful system to detect a wide spectrum of variants from various types of samples.

    DOI: 10.1002/ajmg.a.62982

    PubMed

    researchmap

  • 肺高血圧症における硝酸イソソルビド単回静注効果の再考

    土谷 浩気, 柏村 健, 熊木 隆之, 石塚 光夫, 渡辺 光洋, 酒井 亮平, 久保田 直樹, 大久保 健志, 藤木 伸也, 高山 亜美, 保屋野 真, 石原 嗣郎, 柳川 貴央, 尾崎 和幸, 猪又 孝元

    日本心臓病学会学術集会抄録   70回   O - 1   2022.9

     More details

    Language:Japanese   Publisher:(一社)日本心臓病学会  

    researchmap

  • 機械学習を用いた慢性心不全に続発した肝臓への障害(Cardiac Hepatopathy)の画像解析

    三井田 秀, 上村 博輝, 山崎 文紗子, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 藤木 伸也, 猪又 孝元, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 3 )   152 - 152   2022.8

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

    researchmap

  • 機械学習を用いた慢性心不全に続発した肝臓への障害(Cardiac Hepatopathy)の画像解析

    三井田 秀, 上村 博輝, 山崎 文紗子, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 藤木 伸也, 猪又 孝元, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 3 )   152 - 152   2022.8

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

    researchmap

  • Coagulation factors promote brown adipose tissue dysfunction and abnormal systemic metabolism in obesity

    Yuka Hayashi, Ippei Shimizu, Yohko Yoshida, Ryutaro Ikegami, Masayoshi Suda, Goro Katsuumi, Shinya Fujiki, Kazuyuki Ozaki, Manabu Abe, Kenji Sakimura, Shujiro Okuda, Toshiya Hayano, Kazuhiro Nakamura, Kenneth Walsh, Naja Zenius Jespersen, Søren Nielsen, Camilla Scheele, Tohru Minamino

    iScience   25 ( 7 )   104547 - 104547   2022.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.isci.2022.104547

    researchmap

  • Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial. International journal

    Shinya Fujiki, Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Hiroki Uehara, Ikuko Nakamura, Kazuo Matsunaga, Makoto Suzuki, Takeshi Kashimura, Tohru Minamino, Takayuki Inomata, Koichi Node

    Clinical research in cardiology : official journal of the German Cardiac Society   112 ( 1 )   87 - 97   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: In patients with chronic heart failure (CHF) and type 2 diabetes (T2D), sodium-glucose cotransporter-2 (SGLT2) inhibition improves cardiorenal outcomes, but details of the effects on distinct subsets of body fluid volume remain incomplete. METHODS: This was a post hoc analysis of patients with CHF and T2D in the CANDLE trial (UMIN000017669), an investigator-initiated, multi-center, randomized open-label trial that compared the effect of canagliflozin (100 mg, n = 113) with glimepiride (starting dose: 0.5 mg, n = 120) on changes in N-terminal pro-brain natriuretic peptide. The estimated plasma volume (ePV, calculated with the Straus formula) and estimated extracellular volume (eEV, determined by the body surface area) were compared between treatment groups at weeks 4, 12, and 24. RESULTS: Among 233 patients analyzed, 166 (71.2%) had an ejection fraction (EF) > 50%. Reductions in ePV and eEV were observed only in the canagliflozin group until week 12 (change from baseline at week 12, ePV; - 7.63%; 95% confidence interval [CI], - 10.71 to - 4.55%, p < 0.001, eEV; - 123.15 mL; 95% CI, - 190.38 to - 55.92 mL, p < 0.001). While ePV stopped falling after week 12, eEV continued to fall until week 24 ([change from baseline at week 24] - [change from baseline at week 12], ePV; 1.01%; 95%CI, - 2.30-4.32%, p = 0.549, eEV; - 125.15 mL; 95% CI, - 184.35 to - 65.95 mL, p < 0.001). CONCLUSIONS: Maintenance of a modest reduction in ePV and continuous removal of eEV via chronic SGLT2 inhibition suggests that favorable body fluid regulation contributes to the cardiorenal benefits of SGLT2 inhibitors in patients with CHF, irrespective of EF. TRIAL REGISTRATION: UMIN000017669.

    DOI: 10.1007/s00392-022-02049-4

    PubMed

    researchmap

  • 機械的交互脈を認める拡張型心筋症における左室逆リモデリング(Left ventricular Reverse Remodeling in Dilated Cardiomyopathy with Mechanical Alternans)

    渡辺 光洋, 柏村 健, 加瀬 真弓, 酒井 亮平, 藤木 伸也, 高山 亜美, 久保田 直樹, 大久保 健志, 木村 新平, 保屋野 真, 柳川 貴央, 尾崎 和幸, 猪又 孝元, 石塚 光夫

    日本循環器学会学術集会抄録集   86回   PJ47 - 2   2022.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 下大静脈フィルター長期留置症例における最適な抗凝固療法による血栓イベントの予防(Optimal Anticoagulation Prevents Thrombotic Events in Cases with Long-term Indwelling of Inferior Vena Cava Filters)

    酒井 亮平, 藤木 伸也, 土谷 浩気, 高山 亜美, 木村 新平, 保屋野 真, 柳川 貴央, 柏村 健, 尾崎 和幸, 大倉 裕二, 猪又 孝元

    日本循環器学会学術集会抄録集   86回   MPJ17 - 4   2022.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • Long-Term Outcomes in Patients with Not-Retrieval Inferior Vena Cava Filter Under Anticoagulation.

    Ryohei Sakai, Shinya Fujiki, Takeshi Kashimura, Hiroki Tsuchiya, Kazuyoshi Takahashi, Kazuyuki Ozaki, Yuji Okura, Kazuhiko Hanzawa, Takayuki Inomata

    International heart journal   63 ( 2 )   306 - 311   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Since permanent inferior vena cava (IVC) filters increase deep vein thrombosis (DVT), filter retrieval should be performed as possible. Despite the guideline recommendation, IVC filters are not always retrieved in clinical practice. To date, many patients with not-retrieval IVC filters have been prescribed anticoagulant therapy, but the long-term prognosis, including venous thromboembolism (VTE) and bleeding events, remains unknown. In this study, 195 patients who underwent IVC filter implantation between 2006 and 2017 at 3 institutions in Niigata City have been investigated about their deaths, VTE recurrence, and bleeding events. After peaking 2009, the number of IVC filter implantation gradually decreased. During observational period, there were 158 patients with not-retrieval IVC filters (the overall retrieval rate of 19.0%). The not-retrieval group included significantly older and more patients with cancer compared to the retrieval group. Anticoagulation therapy was continued in 88% of the not-retrieval group. During a mean follow-up of 5.0 years, 6 symptomatic DVT events associated with inadequate control of anticoagulation and 13 bleeding events were observed. A total of 52 patients died and only the presence of cancer was prognostic risk factor. Although long-term anticoagulation therapy may be associated with bleeding events, there were few recurrent VTE under optimal anticoagulation. It is anticipated that even if the IVC filter cannot be retrieved, appropriate anticoagulation is useful for prevention of DVT recurrence despite the risk of bleeding.

    DOI: 10.1536/ihj.21-814

    PubMed

    researchmap

  • Incidence and Risk Factors of Future Need for Long-Term Care Insurance in Japanese Elderly Patients With Left Ventricular Systolic Dysfunction

    Shinya Fujiki, Takeshi Kashimura, Yuji Okura, Kunio Kodera, Hiroshi Watanabe, Komei Tanaka, Shogo Bannai, Taturo Hatano, Takahiro Tanaka, Nobutaka Kitamura, Tohru Minamino, Takayuki Inomata

    Circulation Journal   86 ( 1 )   158 - 165   2021.11

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Circulation Society  

    Background: Heart failure in elderly people causes physical and cognitive dysfunction and often requires long-term care insurance (LTCI); however, among patients with left ventricular (LV) systolic dysfunction, the incidence and risk factors of future LTCI requirements need to be elucidated. Methods and Results: The study included 1,852 patients aged >_65 years with an echocardiographic LV ejection fraction (LVEF) <= 50%; we referred to their LTCI data and those of 113,038 community-dwelling elderly people. During a mean 1.7-year period, 332 patients newly required LTCI (incidence 10.7 per 100 person-years); the incidence was significantly higher than that for the community-dwelling people (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.32-1.64). On multivariate analysis, the risk factors at the time of echocardiography leading to future LTCI requirement were atrial fibrillation (HR, 1.588; 95% CI, 1.279-1.971), history of stroke (HR, 2.02; 95% CI, 1.583-2.576), osteoporosis (HR, 1.738; 95% CI, 1.253-2.41), dementia (HR, 2.804; 95% CI, 2.075-3.789), hypnotics (HR, 1.461; 95% CI, 1.148-1.859), and diuretics (HR, 1.417; 95% CI, 1.132-1.773); however, the LVEF was not a risk factor (HR, 0.997; 95% CI, 0.983-1.011). Conclusions: In elderly patients with LV systolic dysfunction, the incidence of LTCI requirement was more common than that for community-dwelling people; its risk factors did not include LVEF, but included many other non-cardiac comorbidities and therapies, suggesting the need for interdisciplinary cooperation to prevent disabilities.

    DOI: 10.1253/circj.cj-21-0580

    Web of Science

    researchmap

  • Association of adipokines with frailty in heart failure Reviewed International journal

    Shinya Fujiki, Hiroshi Watanabe, Hiroaki Obata, Masayoshi Suda, Wataru Mitsuma, Asako Tomii, Katsuyuki Sakai, Akifumi Uehara, Ippei Shimizu, Takeshi Kashimura, Kazuyuki Ozaki, Tohru Minamino

    Acta Biomed.   92 ( 3 )   e2021195   2021.7

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Background Frailty is a multifactorial physiological syndrome most often associated with age but which has received increasing recognition as a component of chronic illnesses such as heart failure. Patients with heart failure are likely to be frail, irrespective of their age. Adipokine dysregulation, which is associated with frailty, occurs in patients with heart failure. In this study, we tested the hypothesis that adipokines are associated with frailty in patients with heart failure. Methods Thirty-five patients with heart failure (age, 67 ± 14 years; 25 males; left ventricular ejection fraction, 45 ± 19%) were included. Serum adipokine levels, physical performance, and body composition were measured. Results Adiponectin and leptin were inversely correlated with grip strength. Adiponectin was inversely correlated with bone mineral density. Leptin was positively correlated with fat mass. Adipokines were not correlated with skeletal muscle mass. Conclusions Adipokines were associated with frailty in patients with heart failure. Adipokine dysregulation may play a role in the development of frailty in heart failure.

    DOI: 10.23750/abm.v92i3.9228

    PubMed

    researchmap

  • Long-term Outcome of Permanent Inferior Vena Cava Filters; A Single-center Retrospective Observational Study(和訳中)

    酒井 亮平, 藤木 伸也, 石塚 光夫, 加瀬 真弓, 渡辺 光洋, 久保田 直樹, 大久保 健志, 木村 新平, 保屋野 真, 柳川 貴央, 尾崎 和幸

    日本循環器学会学術集会抄録集   85回   OJ86 - 4   2021.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • Validation of Cancer Incidence in Patients with Left Ventricular Systolic Dysfunction(和訳中)

    久保田 直樹, 藤木 伸也, 大倉 裕二, 田中 孔明, 大久保 健志, 木村 新平, 保屋野 真, 柳川 貴央, 柏村 健, 尾崎 和幸, 高橋 和義, 南野 徹

    日本循環器学会学術集会抄録集   85回   OJ29 - 7   2021.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design International journal

    Shinya Fujiki, Kenichi Iijima, Masaaki Okabe, Shinichi Niwano, Kenichi Tsujita, Shigeto Naito, Kenji Ando, Kengo Kusano, Ritsushi Kato, Junichi Nitta, Tetsuji Miura, Takeshi Mitsuhashi, Kazuomi Kario, Yusuke Kondo, Masaki Ieda, Nobuhisa Hagiwara, Toyoaki Murohara, Kazuyoshi Takahashi, Hirofumi Tomita, Yasuchika Takeishi, Toshihisa Anzai, Wataru Shimizu, Masafumi Watanabe, Yoshihiro Morino, Takeshi Kato, Hiroshi Tada, Yoshihisa Nakagawa, Masafumi Yano, Koji Maemura, Takeshi Kimura, Hisako Yoshida, Keiko Ota, Takahiro Tanaka, Nobutaka Kitamura, Koichi Node, Yoshifusa Aizawa, Ippei Shimizu, Daisuke Izumi, Kazuyuki Ozaki, Tohru Minamino

    Diabetes Therapy   11 ( 11 )   2739 - 2755   2020.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    INTRODUCTION: Type 2 diabetes (T2DM) is associated with cardiovascular death, including sudden cardiac death due to arrhythmias. Patients with an implantable cardioverter-defibrillator (ICD) are also at high risk of developing a clinically significant ventricular arrhythmia. It has been reported that sodium-glucose cotransporter 2 (SGLT2) inhibitors can reduce cardiovascular deaths; however, the physiological mechanisms of this remain unclear. It is, however, well known that SGLT2 inhibitors increase blood ketone bodies, which have been suggested to have sympatho-suppressive effects. Empagliflozin (EMPA) is an SGLT2 inhibitor. The current clinical trial titled "Placebo-controlled, double-blind study of empagliflozin (EMPA) and implantable cardioverter-defibrillator (EMPA-ICD) in patients with type 2 diabetes (T2DM)" was designed to investigate the antiarrhythmic effects of EMPA. METHODS: The EMPA-ICD study is a prospective, multicenter, placebo-controlled, double-blind, randomized, investigator-initiated clinical trial currently in progress. A total of 210 patients with T2DM (hemoglobin A1c 6.5-10.0%) will be randomized (1:1) to receive once-daily placebo or EMPA, 10 mg, for 24 weeks. The primary endpoint is the number of clinically significant ventricular arrhythmias for 24 weeks before and 24 weeks after study drug administration, as documented by the ICD. The secondary endpoints of the study are the change from baseline concentrations in blood ketone and catecholamine 24 weeks after drug treatment. CONCLUSION: The EMPA-ICD study is the first clinical trial to assess the effect of an SGLT2 inhibitor on clinically significant ventricular arrhythmias in patients with T2DM and an ICD. TRIAL REGISTRATION: Unique trial number, jRCTs031180120 ( https://jrct.niph.go.jp/latest-detail/jRCTs031180120 ).

    DOI: 10.1007/s13300-020-00924-9

    Web of Science

    PubMed

    researchmap

    Other Link: http://link.springer.com/article/10.1007/s13300-020-00924-9/fulltext.html

  • Complications and Treatments in Heart Failure Patients with Long-term Care Insurance(和訳中)

    藤木 伸也, 大倉 裕二, 古寺 邦夫, 渡部 裕, 田中 孔明, 柏村 健, 尾崎 和幸, 南野 徹

    日本循環器学会学術集会抄録集   84回   PJ16 - 8   2020.7

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • The Pathological Role of Coagulation Factors in Promoting Brown Adipose Tissue Dysfunction and Systemic Metabolic Disorder in Obesity

    Yuka Hayashi, Ippei Shimizu, Yohko Yoshida, Ryutaro Ikegami, Goro Katsuumi, Masayoshi Suda, Shinya Fujiki, Tohru Minamino

    CIRCULATION RESEARCH   125   2019.8

     More details

    Language:English   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Web of Science

    researchmap

  • Failing Left Ventricles Have an Enhanced Post-Stimulation Potentiation Despite Their Impaired Force Frequency Relationship

    Tohru Watanabe, Takeshi Kashimura, Makoto Kodama, Komei Tanaka, Shinya Fujiki, Yuka Hayashi, Hiroaki Obata, Haruo Hanawa, Tohru Minamino

    International Heart Journal   57 ( 3 )   317 - 322   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:International Heart Journal (Japanese Heart Journal)  

    The left ventricular contractile force (LV dP/dt(max)) of patients with left ventricular systolic dysfunction does not increase effectively with an increase in heart rate. In other words, their force-frequency relationship (FFR) is impaired. However, it is unknown whether a longer coupling interval subsequent to tachycardia causes a stronger contraction (post stimulation potentiation, PSP) in a rate-dependent manner.In 16 patients with idiopathic dilated cardiomyopathy (DCM) (48 +/- 2 years old, LVEF 30 +/- 10%) and 6 control patients (58 +/- 4 years old, LVEF 70 +/- 7%), FFR was assessed by right atrial pacing using a micro-manometer-tipped catheter. At each pacing rate, the increase of LV dP/dt(max) over basal LV dP/dt (Delta FFR) and the increase of LV dP/dt(max) of the first beat after pacing cessation over LV dP/dt(max) during pacing (Delta PSP) were evaluated.Patients with DCM had smaller LV dP/dt(max) at baseline (872 +/- 251 versus 1370 +/- 123 mmHg/second, P = 0.0002) and developed smaller Delta FFR (eg, at 120/minute, 77 +/- 143 versus 331 +/- 131 mmHg/second, P = 0.0011). In contrast, they showed a rate-dependent increase of LV dP/dt(max) of PSP and had greater Delta PSP (eg, at 120/minute, 294 +/- 173 versus -152 +/- 131 mmHg/second, P < 0.0001).Failing left ventricles develop little contractile force during tachycardia despite their rate-dependent enhancement in post-stimulation potentiation, suggesting that refractoriness of contractile force underlies impaired FFR.

    DOI: 10.1536/ihj.15-374

    Web of Science

    researchmap

  • Diastolic Wall Strain Predicts Clinical Worsening of Fulminant Myocarditis: Exploratory Findings from Four Case Reports

    Shinya Fujiki, Hiroaki Obata, Takeshi Kashimura, Komei Tanaka, Haruo Hanawa, Tohru Minamino

    JOURNAL OF CARDIAC FAILURE   21 ( 10 )   S164 - S165   2015.10

     More details

    Language:English   Publisher:CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS  

    DOI: 10.1016/j.cardfail.2015.08.120

    Web of Science

    researchmap

  • Acute Hemodynamic Effects of Adaptive Servo Ventilation in a Patient with Atrial Septal Defect

    Shinya Fujiki, Hiroaki Obata, Takeshi Kashimura, Ritsuo Watanabe, Osamu Ogawa, Haruo Hanawa, Tohru Minamino

    JOURNAL OF CARDIAC FAILURE   20 ( 10 )   S210 - S210   2014.10

     More details

    Language:English   Publisher:CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS  

    DOI: 10.1016/j.cardfail.2014.07.428

    Web of Science

    researchmap

  • Characteristics of Patient with Ventricular Fibrillation in Takotsubo Cardiomyopathy

    Shinya Fujiki, Hiroaki Obata, Takeshi Kashimura, Tadashi Sato, Kenji Ojima, Haruo Hanawa, Tohru Minamino

    JOURNAL OF CARDIAC FAILURE   19 ( 10 )   S164 - S165   2013.10

     More details

    Language:English   Publisher:CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS  

    DOI: 10.1016/j.cardfail.2013.08.442

    Web of Science

    researchmap

  • 'Crystal lattice engineering,' an approach to engineer protein crystal contacts by creating intermolecular symmetry: crystallization and structure determination of a mutant human RNase 1 with a hydrophobic interface of leucines. International journal

    Hidenori Yamada, Taro Tamada, Megumi Kosaka, Kohei Miyata, Shinya Fujiki, Masaru Tano, Masayuki Moriya, Mamoru Yamanishi, Eijiro Honjo, Hiroko Tada, Takeshi Ino, Hiroshi Yamaguchi, Junichiro Futami, Masaharu Seno, Takashi Nomoto, Tomoko Hirata, Motonobu Yoshimura, Ryota Kuroki

    Protein science : a publication of the Protein Society   16 ( 7 )   1389 - 97   2007.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A protein crystal lattice consists of surface contact regions, where the interactions of specific groups play a key role in stabilizing the regular arrangement of the protein molecules. In an attempt to control protein incorporation in a crystal lattice, a leucine zipper-like hydrophobic interface (comprising four leucine residues) was introduced into a helical region (helix 2) of the human pancreatic ribonuclease 1 (RNase 1) that was predicted to form a suitable crystallization interface. Although crystallization of wild-type RNase 1 has not yet been reported, the RNase 1 mutant having four leucines (4L-RNase 1) was successfully crystallized under several different conditions. The crystal structures were subsequently determined by X-ray crystallography by molecular replacement using the structure of bovine RNase A. The overall structure of 4L-RNase 1 is quite similar to that of the bovine RNase A, and the introduced leucine residues formed the designed crystal interface. To characterize the role of the introduced leucine residues in crystallization of RNase 1 further, the number of leucines was reduced to three or two (3L- and 2L-RNase 1, respectively). Both mutants crystallized and a similar hydrophobic interface as in 4L-RNase 1 was observed. A related approach to engineer crystal contacts at helix 3 of RNase 1 (N4L-RNase 1) was also evaluated. N4L-RNase 1 also successfully crystallized and formed the expected hydrophobic packing interface. These results suggest that appropriate introduction of a leucine zipper-like hydrophobic interface can promote intermolecular symmetry for more efficient protein crystallization in crystal lattice engineering efforts.

    PubMed

    researchmap

▶ display all

MISC

  • トクシュウ イマ ダカラ コソ キキタイ シンフゼン シンリョウ ノ コト 。 ; チリョウ

    71 ( 2 )   234 - 243   2023.4

     More details

  • 心筋生検でDirect Fast Scarlet染色により検出される細胞質顆粒の検討

    柏村 健, 加瀬 真弓, 渡辺 光洋, 石塚 光夫, 酒井 亮平, 藤木 伸也, 高山 亜美, 猪又 孝元

    日本内分泌学会雑誌   97 ( 5 )   1508 - 1508   2022.3

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • Optimal Anticoagulation Prevents Thrombotic Events in Cases with Long-term Indwelling of Inferior Vena Cava Filters(和訳中)

    酒井 亮平, 藤木 伸也, 土谷 浩気, 高山 亜美, 木村 新平, 保屋野 真, 柳川 貴央, 柏村 健, 尾崎 和幸, 大倉 裕二, 猪又 孝元

    日本循環器学会学術集会抄録集   86回   MPJ17 - 4   2022.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • Left ventricular Reverse Remodeling in Dilated Cardiomyopathy with Mechanical Alternans(和訳中)

    渡辺 光洋, 柏村 健, 加瀬 真弓, 酒井 亮平, 藤木 伸也, 高山 亜美, 久保田 直樹, 大久保 健志, 木村 新平, 保屋野 真, 柳川 貴央, 尾崎 和幸, 猪又 孝元, 石塚 光夫

    日本循環器学会学術集会抄録集   86回   PJ47 - 2   2022.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • Temporal Change in Cardiac 18 F-FDG-PET Accumulation Just after Prednisolone and its Clinical Relevance in Cardiac Sarcoidosis(和訳中)

    石塚 光夫, 柏村 健, 渡辺 光洋, 加瀬 真弓, 酒井 亮平, 大久保 健志, 藤木 伸也, 高山 亜美, 猪又 孝元

    日本循環器学会学術集会抄録集   86回   PJ24 - 6   2022.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 栄養状態による心不全患者の長期ケアの予測(Nutritional Status Predicts Long-term Care in Patients with Heart Failure)

    藤木 伸也, 藤木 伸也, 大倉 裕二, 古寺 邦夫, 渡部 裕, 田中 孔明, 坂内 省五, 田中 崇裕, 北村 信隆, 南野 徹

    日本循環器学会学術集会抄録集   85回   OJ81 - 1   2021.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 栄養状態による心不全患者の長期ケアの予測(Nutritional Status Predicts Long-term Care in Patients with Heart Failure)

    藤木 伸也, 藤木 伸也, 大倉 裕二, 古寺 邦夫, 渡部 裕, 田中 孔明, 坂内 省五, 田中 崇裕, 北村 信隆, 南野 徹

    日本循環器学会学術集会抄録集   85回   OJ81 - 1   2021.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 左室収縮機能障害患者におけるがん罹患率の検証(Validation of Cancer Incidence in Patients with Left Ventricular Systolic Dysfunction)

    久保田 直樹, 藤木 伸也, 大倉 裕二, 田中 孔明, 大久保 健志, 木村 新平, 保屋野 真, 柳川 貴央, 柏村 健, 尾崎 和幸, 高橋 和義, 南野 徹

    日本循環器学会学術集会抄録集   85回   OJ29 - 7   2021.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 永久留置型下大静脈フィルターの長期成績 単一施設での後向き観察研究(Long-term Outcome of Permanent Inferior Vena Cava Filters; A Single-center Retrospective Observational Study)

    酒井 亮平, 藤木 伸也, 石塚 光夫, 加瀬 真弓, 渡辺 光洋, 久保田 直樹, 大久保 健志, 木村 新平, 保屋野 真, 柳川 貴央, 尾崎 和幸

    日本循環器学会学術集会抄録集   85回   OJ86 - 4   2021.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 肥満において凝固第Xa因子は褐色脂肪組織の機能を阻害し全身性代謝機能障害を誘発する(Factor Xa inhibits brown adipose tissue function and induces systemic metabolic dysfunction in obesity)

    林 由香, 清水 逸平, 吉田 陽子, 勝海 悟郎, 須田 将吉, 仲尾 政晃, 蕭 詠庭, 藤木 伸也, 南野 徹

    日本抗加齢医学会総会プログラム・抄録集   20回   222 - 222   2020.9

     More details

    Language:English   Publisher:(一社)日本抗加齢医学会  

    researchmap

  • 肥満における褐色脂肪組織機能低下と全身代謝異常の誘発に凝固因子が果たす重要な役割(The Critical Roles of Coagulation Factors in Inducing Brown Adipose Tissue Dysfunction and Systemic Metabolic Disorder in Obesity)

    林 由香, 清水 逸平, 吉田 陽子, 勝海 悟郎, 須田 将吉, 藤木 伸也, 南野 徹

    日本循環器学会学術集会抄録集   84回   PJ9 - 8   2020.7

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 介護保険に加入している心不全患者の合併症と治療(Complications and Treatments in Heart Failure Patients with Long-term Care Insurance)

    藤木 伸也, 大倉 裕二, 古寺 邦夫, 渡部 裕, 田中 孔明, 柏村 健, 尾崎 和幸, 南野 徹

    日本循環器学会学術集会抄録集   84回   PJ16 - 8   2020.7

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • COVID-19 and cardiovascular disease

    Anti-aging medicine   16 ( 3 )   365 - 370   2020.6

  • Diabetes as the etiology of heart failure

    87 ( 4 )   425 - 431   2020.4

  • 心不全患者における栄養評価法の検討(第2報)

    曽根 あずさ, 高山 亜美, 鶴田 恵, 武田 安永, 今井 十夢, 藤木 伸也, 柏村 健, 尾崎 和幸, 小師 優子, 南野 徹

    日本病態栄養学会誌   23 ( Suppl. )   S - 67   2020.1

     More details

    Language:Japanese   Publisher:(一社)日本病態栄養学会  

    researchmap

  • 肥満症におけるXa因子は褐色脂肪組織機能を抑制し全身の代謝機能障害を誘導する(Factor Xa Inhibits Brown Adipose Tissue Function and Induces Systemic Metabolic Dysfunction in Obesity)

    林 由香, 清水 逸平, 吉田 陽子, 池上 龍太郎, 勝海 悟郎, 須田 将吉, 藤木 伸也, 南野 徹

    日本循環器学会学術集会抄録集   83回   PJ101 - 3   2019.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

    researchmap

  • 心不全患者における栄養評価法の検討

    曽根 あずさ, 高山 亜美, 武田 安永, 藤木 伸也, 柏村 健, 尾崎 和幸, 村山 稔子, 南野 徹

    日本病態栄養学会誌   22 ( Suppl. )   S - 69   2019.1

     More details

    Language:Japanese   Publisher:(一社)日本病態栄養学会  

    researchmap

  • 肥満に伴う褐色脂肪組織の白色化における血液凝固第Xa因子の意義

    林 由香, 清水 逸平, 吉田 陽子, 池上 龍太郎, 勝海 悟郎, 須田 将吉, 藤木 伸也, 南野 徹

    肥満研究   24 ( Suppl. )   225 - 225   2018.9

     More details

    Language:Japanese   Publisher:(一社)日本肥満学会  

    researchmap

  • 肥満に伴う褐色脂肪組織の白色化における血液凝固第Xa因子の意義

    林 由香, 清水 逸平, 吉田 陽子, 池上 龍太郎, 勝海 悟郎, 須田 将吉, 藤木 伸也, 南野 徹

    肥満研究   24 ( Suppl. )   225 - 225   2018.9

     More details

    Language:Japanese   Publisher:(一社)日本肥満学会  

    researchmap

  • Emery-Dreifuss型筋ジストロフィに合併し、急激な心機能低下を認めたラミン関連心筋症の1例

    南場 一美, 柏村 健, 大野 由香子, 藤木 伸也, 渡邊 達, 林 由香, 田中 孔明, 小幡 裕明, 佐藤 光希, 和泉 大輔, 塙 晴雄, 南野 徹

    心臓   49 ( 4 )   405 - 410   2017.4

     More details

    Language:Japanese   Publisher:(公財)日本心臓財団  

    症例は26歳女性。7歳時に先天性ミオパチーと診断された。5年前より心拍数40/分台の洞徐脈を指摘されていた。入院5ヵ月前より心不全症状、前失神症状が出現し、ペースメーカ植込みが施行された。その際LVDd/Ds=5.4/3.7cm、EF=58%と心機能は保たれていたが、3ヵ月後にはLVDd/Ds=5.3/4.1cm、EF=36%と急激に心機能は悪化し、心不全も徐々に増悪した。遺伝子検査にてLMNA遺伝子変異を認め、ラミン関連心筋症と診断した。また、幼児期より緩徐進行性の筋力低下や関節拘縮を呈し、心伝導障害・心筋症の出現とLMNA遺伝子異常を認め、既存のミオパチーをEmery-Dreifuss型筋ジストロフィと診断した。2ヵ月後には安静時呼吸苦が出現し、救急搬送された。LVDd/Ds=4.9/4.2cm、EF=28%と心機能はさらに悪化を認めた。ドブタミン併用下に、静注利尿薬、トルバプタン、ミルリノンを使用し、CRT-Dへのupgradeを施行し、徐々に心不全症状は改善した。カルベジロールを10mgまで漸増したが、低心拍出による全身倦怠感、腎機能増悪が出現し、静注強心薬からの離脱に難渋した。経口強心薬を併用しつつ、静注強心薬から離脱し、入院6ヵ月後に退院した。Emery-Dreifuss型筋ジストロフィに合併し、急激な心機能低下を認めたラミン関連心筋症の1例を経験したので報告する。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J00679&link_issn=&doc_id=20170420180017&doc_link_id=%2Fah2sinzd%2F2017%2F004904%2F019%2F0405-0410%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fah2sinzd%2F2017%2F004904%2F019%2F0405-0410%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 6 左心系弁膜症術後遠隔期の高度三尖弁逆流に対する外科治療患者9例の検討 (Ⅰ.一般演題, 第288回新潟循環器談話会)

    新潟医学会雑誌   131 ( 3 )   195 - 195   2017.3

  • 大動脈弁狭窄を合併した閉塞性肥大型心筋症に対し経皮的中隔心筋焼灼術にて症状の改善が得られた1例

    仲尾 政晃, 柏村 健, 藤木 伸也, 渡辺 達, 林 由香, 田中 孔明, 小幡 裕明, 尾崎 和幸, 塙 晴雄, 南野 徹

    日本心臓病学会学術集会抄録   64回   P - 500   2016.9

     More details

    Language:Japanese   Publisher:(一社)日本心臓病学会  

    researchmap

  • 機能性僧帽弁閉鎖不全症を伴うEF10%台の低心機能拡張型心筋症に対して、弁下組織温存僧帽弁置換術が有効であった2例

    南場 一美, 柏村 健, 長谷川 祐紀, 藤木 伸也, 渡邊 達, 林 由香, 田中 孔明, 小幡 裕明, 佐藤 光希, 和泉 大輔, 南野 徹, 長澤 綾子, 佐藤 裕喜, 岡本 竹司, 青木 賢治, 名村 理

    日本心臓病学会学術集会抄録   64回   P - 302   2016.9

     More details

    Language:Japanese   Publisher:(一社)日本心臓病学会  

    researchmap

  • 心不全を併発している高齢患者の自立歩行を守るための循環器予防研究

    小幡 裕明, 藤木 伸也, 上原 彰史, 清野 健二, 佐藤 三奈希, 坂野 周平, 三間 渉, 冨井 亜佐子, 堺 勝之, 和泉 徹, 南野 徹

    日本循環器病予防学会誌   51 ( 2 )   111 - 111   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本循環器病予防学会  

    researchmap

  • 栄養障害を来たした慢性心不全患者の身体機能低下と関連する体液因子の検討

    藤木 伸也, 小幡 裕明, 須田 将吉, 三間 渉, 冨井 亜佐子, 堺 勝之, 上原 彰史, 南野 徹

    日本循環器病予防学会誌   51 ( 2 )   126 - 126   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本循環器病予防学会  

    researchmap

  • 2 繰り返すステント血栓症に対するプラスグレルのCYP2C19^*2/^*2遺伝子多型への影響について(Ⅰ.一般演題, 第282回新潟循環器談話会)

    新潟医学会雑誌   129 ( 10 )   607 - 607   2015.10

  • 8 閉塞性肥大型心筋症に合併した感染性心内膜炎の1例(Ⅱ.テーマ演題「心筋症」, 第282回新潟循環器談話会)

    新潟医学会雑誌   129 ( 10 )   610 - 610   2015.10

  • 重篤な合併症によりICU管理が必要であった感染性心内膜炎の3例

    渡辺 律雄, 五十嵐 聖, 藤木 伸也, 富川 千絵, 小川 理, 曽川 正和

    日本集中治療医学会雑誌   22 ( Suppl. )   [DP96 - 3]   2015.1

     More details

    Language:Japanese   Publisher:(一社)日本集中治療医学会  

    researchmap

  • 1 救命できた aborted sudden death の集計(I.一般演題,第269回新潟循環器談話会)

    新潟医学会雑誌   126 ( 5 )   269 - 269   2012.5

▶ display all

Presentations

  • 地域連携を意識した心不全管理 高度急性期病院の立場から Invited

    藤木伸也

    第5回日本在宅医療連合学会大会 2023.6  2023.6 

     More details

    Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • 新潟県の循環器病診療体制の充実に向けて -クラウドファンディングによる人材育成を通じた心臓リハビリテーションの活性化- Invited

    藤木伸也

    第3回新潟SDGsアワード表彰式  2023.3 

     More details

    Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • クラウドファンディングによる地域心リハ活性と人材育成 Invited

    藤木伸也

    第267回日本循環器学会関東甲信越地方会  2023.2 

     More details

    Presentation type:Symposium, workshop panel (public)  

    researchmap

  • 無症候例での薬剤構成 Invited

    藤木伸也

    第26回日本心不全学会学術集会  2022.10 

     More details

    Presentation type:Symposium, workshop panel (nominated)  

    researchmap

Awards

  • 第3回新潟SDGsアワード 社会部門・優秀賞

    2023.3   一般社団法人 地域創生プラットフォームSDGsにいがた   新潟県の循環器病診療体制の充実へ向けてークラウドファンディングによる人材育成を通じた心臓リハビリテーションの活性化ー

    新潟大学大学院医歯学総合研究科, 循環器内科学

     More details

  • 第257回日本循環器学会関東甲信越地方会 Clinical Research Award

    2020.9  

     More details

  • 第25回日本心臓リハビリテーション学会学術集会 優秀演題賞

    2019.7  

     More details

 

Teaching Experience (researchmap)

 

Media Coverage